Abstract: Methods of treatment and prevention and assays to select optimal compounds for treating or preventing infections from severe acute respiratory syndrome (SARS)-related coronaviruses (SARS-CoV), such as SARS-CoV-2, that interfere with the activity of the nidovirus RdRp-associated nucleotidyltransferase (NiRAN) domain of non-structural protein 12 (nsp12). The invention establishes for the first time herein the foundational discovery of the mechanism of action of the NiRAN-domain, and how it can be used in pharmaceutical therapy against SARS-CoV infection, including a SARS-CoV-2 infection, or exposure.

Abstract: This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R1-R3 are as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and their use for the preparation of a medication for testing and/or preventing a viral infection in a patient. The invention also provides methods for making these compounds. In particular, the invention provides an H-phosphinate precursor intermediate of formula (II) wherein B is a purine or pyrimidine base as defined herein and R1 is selected from the group comprising a hydrogen atom, and a methyl, ethyl, hydroxymethyl, hydroxyethyl and C1-6haloalkyl group.

Abstract: The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase activity of an isolated and purified polypeptide from flavivirus is also disclosed.

Abstract: The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase activity of an isolated and purified polypeptide from flavivirus is also disclosed.

Abstract: This invention relates to a purine or pyrimidine phosphonate compound of formula (I) or pharmaceutically acceptable salt thereof; wherein B, X, and R1-R3 are as defined in classes and subclasses herein. These compounds may be used as antiviral precursors. The invention also relates to therapeutic compositions of these compounds and their use for the preparation of a medication for testing and/or preventing a viral infection in a patient. The invention also provides methods for making these compounds. In particular, the invention provides an H-phosphinate precursor intermediate of formula (II) wherein B is a purine or pyrimidine base as defined herein and R1 is selected from the group comprising a hydrogen atom, and a methyl, ethyl, hydroxymethyl, hydroxyethyl and C1-6haloalkyl group.

Abstract: The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase activity of an isolated and purified polypeptide from flavivirus is also disclosed.

Abstract: The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase activity of an isolated and purified polypeptide from flavivirus is also disclosed.

Abstract: This invention concerns an isolated and purified polypeptide capable of acting as a guanylyltransferase and methyltransferase comprising capping enzyme of flavivirus (CEF). The invention also concerns the use of such polypeptide to identify biologically active molecule wich can be used in the treatment or the prevention of diseases resulting from Flavivirus infection.

Abstract: This invention concerns an isolated and purified polypeptide capable of acting as a guanylyltransferase and methyltransferase comprising capping enzyme of flavivirus (CEF). The invention also concerns the use of such polypeptide to identify biologically active molecule wich can be used in the treatment or the prevention of diseases resulting from Flavivirus infection.

Abstract: The isolation and purification of two domains from a from a flavivirus is provided. Each domain can function independently. Moreover, one domain codes for a sequence that provide polymerase activity. A process for screening possible modulators of the polymerase activity of an isolated and purified polypeptide from flavivirus is also disclosed.

Abstract: The invention is directed to the use of RNA or DNA polymerases having 3'-intrinsic editing activity (3'-IEA) in the presence or absence of a deactivating agent to remove a protecting group from the 3'-position of oligo- polyribo- or deoxyribonnucleotides. The use is connected with the incorporation of dNTPs into DNA templates in order to determine the concentration and/or sequence of said templates. In particular the use is concerned with an improved non gel-based sequencing method.

Abstract: Deoxyribonucleotide 5' triphosphate (dNTP) or ribonucleotide 5' triphosphate (NTP) esters for use in a nucleic acid sequencing process without use of a gel and having one o formulae (I), (II), (III) or (IV).